Femasys Inc. reported a 52% increase in annual revenue to $1.63 million for FY2024, driven primarily by FemaSeed product sales of $0.51 million following its commercialization. The net loss widened to $18.82 million from $14.25 million in 2023, reflecting increased investments in commercialization and R&D activities. The company ended the year with $3.45 million in cash.In March 2025, Femasys achieved a significant milestone with CE mark certification under EU MDR for the FemBloc delivery system, marking its first regulatory approval worldwide. The company has also completed an expedited G12 Special MDR Audit for the FemBloc blended polymer component, with CE mark approval expected by mid-2025. Strategic distribution partnerships were established in Spain to support the European commercialization.The company continues to advance its pivotal U.S. clinical trial for FemBloc permanent birth control, while expanding commercial partnerships for FemaSeed with prominent fertility centers including Boston IVF, HRC Fertility, and CNY Fertility. Management expects current cash resources and anticipated revenues to fund operations into Q3 2025, though additional financing will be required to support ongoing development and commercialization efforts.

Femasys Inc. reported a 52% increase in annual revenue to $1.63 million for FY2024, driven primarily by FemaSeed product sales of $0.51 million following its commercialization. The net loss widened to $18.82 million from $14.25 million in 2023, reflecting increased investments in commercialization and R&D activities. The company ended the year with $3.45 million in cash.In March 2025, Femasys achieved a significant milestone with CE mark certification under EU MDR for the FemBloc delivery system, marking its first regulatory approval worldwide. The company has also completed an expedited G12 Special MDR Audit for the FemBloc blended polymer component, with CE mark approval expected by mid-2025. Strategic distribution partnerships were established in Spain to support the European commercialization.The company continues to advance its pivotal U.S. clinical trial for FemBloc permanent birth control, while expanding commercial partnerships for FemaSeed with prominent fertility centers including Boston IVF, HRC Fertility, and CNY Fertility. Management expects current cash resources and anticipated revenues to fund operations into Q3 2025, though additional financing will be required to support ongoing development and commercialization efforts.